The GROWTH consortium, funded by the European Commission (2019-2023), is made up to train a new generation of researchers working on new pathological insights, biomarker diagnostics and personalized nutritional interventions for intestinal failure in neonates and preterm infants.
Academic and industry partners, covering various disciplines ranging from fundamental research to clinical paediatrics and analytical chemistry to organoid and gut-on-chip applications, have teamed up in the European Union.
GROWTH aims to set-up a new European platform that trains young scientists in the industry-led exploration of innovative routes to fully exploit the potential of early life nutrition to prevent inflammatory disease. GROWTH coordinates 8 individual research projects.
If you have any questions you can fill in the form or mail us directly: email@example.com.
Mohammed Ghiboub, together with Dr Bruno Sovran and Prof. Wouter de Jonge, published a very nice review on nutritional interventions targeting Tryptophan (Trp) metabolism and Aryl Hydrocarbon-Receptor (AhR) signaling (Nutrients 2020, 12(9), 2846; https://doi.org/10.3390/nu12092846).
Recently, a cutting-edge technology was installed at AMC to define the volatiles emitted from the feces of healthy donors and patients with gastrointestinal disease. Owlstone Medical, one of the GROWTH collaborators, has developed this technology and is worldwide one of the pioneering companies in breath biopsy applications in early disease detection and precision medicine.
This course is for anyone interested in subjects related to the human microbiome, how food can influence it, and how this resultantly impacts on human health.
Bringing stakeholders together to shape future research and innovation policy.